Catalyst
Monitor results from this trial for insights on IAP overexpression's impact on recurrence rates and potential clinical applications.
Date
June 23, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.